Skip to main content
Premium Trial:

Request an Annual Quote

Celera, SomaLogic Pen Multi-Year Proteomics Deal

NEW YORK, Aug 16. – Proteomics company SomaLogic said Thursday it had signed a multi-year deal to provide Celera with early access to its aptamers and aptamer arrays.

In exchange, SomaLogic will receive access to Celera’s sequence data and proteins with which it can develop additional aptamers.

Aptamers are DNA or RNA molecules that have been artificially manipulated to bind with molecules and viruses. They are considered to have many potential uses in medicine and diagnostics.

SomaLogic's aptamer technology uses nucleic acids to bind to distinct proteins. Assembled in an array format, the company said its approach is designed to allow researchers to detect thousands of proteins and link them with particular diseases.

"SomaLogic's aptamer technology complements our genomics and proteomics programs by providing a unique approach for identifying expression and function of multiple proteins likely to play a role in major disease," Craig Venter, Celera's president and chief scientific officer, said in a statement. 

"This agreement should strengthen our proteomics capability and helps our expansion in drug discovery," he added. 

SomaLogic, of Boulder, Colo., was established in 1999. The company is also using its aptamer research to develop diagnostic tools. 

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.